A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: A randomized controlled trial

Osteoporosis International

Volumn 13, Issue 12, 2002, Pages 971-979

  Fukunaga, M ^a   Kushida, K ^b   Kishimoto, H ^c   Shiraki, M ^d   Taketani, Y ^e   Minaguchi, H ^f   Inoue, T ^g   Morita, R ^h   Morii, H ⁱ   Yamamoto, K ^j   Ohashi, Y ^e   Orimo, H ^k  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d Res Inst Pract Involutional Dis   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g Aoyama General Hospital   (Japan)

^h SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

ⁱ OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j TOTTORI UNIVERSITY   (Japan)

^k Tokyo Metropolitan Institute of Gerontology   (Japan)

more..

Author keywords

Bisphosphonate; Bone mineral density; Comparative study; Etidronate; Japanese; Osteoporosis; Risedronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM LACTATE; ETIDRONIC ACID; PEPTIDE; RISEDRONIC ACID;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BIOCHEMISTRY; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MARKETING; DRUG TOLERANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; INCIDENCE; JAPAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TIME;

ADULT; AGED; BIOLOGICAL MARKERS; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; SPINAL FRACTURES;

EID: 0036931733     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980200135     Document Type: Article

References (37)

1. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Am J Med 1991;90:107-10.
2. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
3. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
4. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
5. Storm T, Kollerup G, Thamsborg G, et al. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J Rheumatol 1996;23:1560-4.
6. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
7. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
8. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-50.
9. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101:488-501.
10. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 1999;282:1344-52.
11. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
12. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:1895-1900.
13. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
14. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
15. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785-95.
16. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 1998.
17. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42:2309-18.
18. Reid DM, Hughes RA, Laan RFJM, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 2000;15:1006-13.
19. Shiraki M, Fukunaga M, Kushida K, et al. A double-blind dose-ranging study of risedronate in Japanese patients with involutional osteoporosis [abstract P93SU]. Osteoporos Int 2002;13(Suppl 1):S33.
20. Orimo H, Sugioka Y, Fukunaga M, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-50.
21. Uebelhart D, Gineyts E, Chapuy M-C, et al. Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
22. Tietz NW, Rinker AD, Shaw LM. IFCC methods for the measurement of catalytic concentration of enzymes. 5. IFCC method for alkaline phosphatase. J Clin Chem Clin Biochem 1983;21:731-48.
23. Sietsema WK, Ebetino FH, Salvagno AM, et al. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res 1989;15:389-96.
24. Garnero P, Shin WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
25. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000;85:3537-40.
26. Shiraki M, Kushida K, Fukunaga M, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 1999;10:183-92.
27. Ross PD, Davis JW, Vogel JM, Wasnich RD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tissue Int 1990;46:149-61.
28. Melton LJ III, Atkinson EJ, O'Fallon WM, et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993;8:1227-33.
29. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
30. Fujita T, Orimo H, Inoue T, et al. Double-blind multicenter comparative study with alfacalcidol of etidronate disodium (EHDP) in involutional osteoporosis. Clin Eval 1993;21:261-302.
31. Watts N, Bockman R, Smith C, et al. BMD change explains only a fraction of the observed fracture risk reduction in risedronate-treated patients [abstract 546 (510)]. Osteoporos Int 2000;11(Suppl 2):S203.
32. Cummings SR, Black DM, Pearson JB, et al. How much of the reduction in risk of vertebral fractures by alendronate is explained by increased spine BMD? J Bone Miner Res 1999;14 (Suppl 1):S159.
33. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999;42:1246-54.
34. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
35. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267-76.
36. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001;20:3175-88.
37. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17:1-10.